Merck & Co. Files 8-K on Financials
Ticker: MRK · Form: 8-K · Filed: Feb 4, 2025 · CIK: 310158
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
Related Tickers: MRK
TL;DR
Merck dropped its 8-K detailing financial results. Check the filings for the numbers.
AI Summary
Merck & Co., Inc. filed an 8-K on February 4, 2025, to report on its results of operations and financial condition. The filing includes financial statements and exhibits, detailing the company's financial performance. Specific financial figures and operational details are provided within the accompanying documents.
Why It Matters
This filing provides investors with crucial updates on Merck's financial health and operational performance, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or unusual risks.
Key Players & Entities
- Merck & Co., Inc. (company) — Filer
- 2000 GALLOPING HILL ROAD (address) — Business Address
- KENILWORTH (city) — Business Address City
- NJ (state) — Business Address State
- 07033 (zip_code) — Business Address Zip
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Merck & Co., Inc.'s Results of Operations and Financial Condition, along with providing Financial Statements and Exhibits.
When was this 8-K filing submitted?
This 8-K filing was submitted on February 4, 2025.
What is Merck & Co., Inc.'s Standard Industrial Classification code?
Merck & Co., Inc.'s Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
What is Merck & Co., Inc.'s fiscal year end?
Merck & Co., Inc.'s fiscal year ends on December 31.
What is the SEC file number for Merck & Co., Inc.?
The SEC file number for Merck & Co., Inc. is 001-06571.
Filing Stats: 614 words · 2 min read · ~2 pages · Grade level 8.5 · Accepted 2025-02-04 06:45:47
Key Financial Figures
- $0.50 — nge on which registered Common Stock ($0.50 par value) MRK New York Stock Exchang
Filing Documents
- tm255059d1_8k.htm (8-K) — 39KB
- tm255059d1_ex99-1.htm (EX-99.1) — 554KB
- tm255059d1_ex99-2.htm (EX-99.2) — 580KB
- tm255059d1_ex99-1img001.jpg (GRAPHIC) — 3KB
- 0001104659-25-008863.txt ( ) — 1490KB
- mrk-20250204.xsd (EX-101.SCH) — 5KB
- mrk-20250204_def.xml (EX-101.DEF) — 28KB
- mrk-20250204_lab.xml (EX-101.LAB) — 39KB
- mrk-20250204_pre.xml (EX-101.PRE) — 27KB
- tm255059d1_8k_htm.xml (XML) — 11KB
02. Results of Operations and Financial
Item 2.02. Results of Operations and Financial Condition. The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02. Incorporated by reference is a press release issued by Merck & Co., Inc. on February 4, 2025, regarding earnings for the fourth quarter and year end of 2024, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2. This information shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit 99.1 Press release issued February 4, 2025, regarding earnings for the fourth quarter and year end of 2024 Exhibit 99.2 Certain supplemental information not included in the press release Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Merck & Co., Inc. Date: February 4, 2025 By: /s/ Kelly E. W. Grez Kelly E. W. Grez Corporate Secretary